For the Treatment of Hyperinsulinemias
CRN02481 represents a new class of oral selective nonpeptide somatostatin type 5 receptor, or sst5, agonists currently in preclinical development to treat congenital hyperinsulinism, or CHI. This is a devastating rare disease in which infants are born with mutations that cause excess secretion of the pancreatic hormone insulin resulting in profound hypoglycemia, a very low level of blood glucose. This can lead to seizures, developmental disorders, learning disabilities, coma and even death.
CHI occurs in approximately 1 in 30,000 to 50,000 new births in the United States. We believe an orally available sst5 agonist would provide an important new therapeutic option that inhibits insulin secretion while avoiding glucagon suppression, allowing these patients to maintain normal glucose levels and possibly avoid pancreatectomy, the surgical removal of all or a part of the pancreas.